Tag #Leqembi

Showing 1 to 4 of 4 results

lemonde.fr

🌐 75% Global Worthiness

Sep 9, 13:20

France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi

France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.

France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi

France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the HAS's decision on Leqembi's availability in France?

The HAS's rejection of accelerated approval means Leqembi will not have immediate access and reimbursement in France. This decision delays broader patient access, pending a standard approval process involving further negotiations.

zeit.de

🌐 85% Global Worthiness

Aug 30, 07:15

Lecanemab (Leqembi) Alzheimer Drug Launches in Germany

Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.

Lecanemab (Leqembi) Alzheimer Drug Launches in Germany

Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Lecanemab's launch in Germany?

Lecanemab, marketed as Leqembi, is available in Germany and Austria as of September 1st. However, its impact is limited to approximately 200,000 of Germany's one million Alzheimer's patients due to eligibility criteria (only those with zero or one copy of the ApoE4 gene) and high costs (around €34,000 per year per patient).

zeit.de

🌐 85% Global Worthiness

Aug 31, 10:20

Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's

Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.

Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's

Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.

Progress

28% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Lecanemab's availability in Germany and Austria?

Lecanemab, under the trade name Leqembi, will be available in Germany and Austria from September 1st, offering a new treatment option for approximately 250,000 Germans with early-stage Alzheimer's who meet specific criteria (mild cognitive impairment and at most one copy of the ApoE4 gene). The drug, costing roughly €24,000 per patient annually plus €10,000 for tests and procedures, will initially be covered by health insurance.

npr.org

🌐 75% Global Worthiness

Feb 26, 13:09

Leqembi's Varied Efficacy in Alzheimer's Treatment Highlighted by Patient Case

Sue Bell, diagnosed with early-stage Alzheimer's in 2019, participated in a Leqembi clinical trial from 2020 to 2024, experiencing varied treatment benefits before discontinuing due to declining efficacy, highlighting the drug's limitations despite its approval in 2023.

Leqembi's Varied Efficacy in Alzheimer's Treatment Highlighted by Patient Case

Sue Bell, diagnosed with early-stage Alzheimer's in 2019, participated in a Leqembi clinical trial from 2020 to 2024, experiencing varied treatment benefits before discontinuing due to declining efficacy, highlighting the drug's limitations despite its approval in 2023.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Sue Bell's experience illustrate the complexities and limitations of current Alzheimer's treatments?

Leqembi, approved in 2023, targets beta-amyloid plaques associated with Alzheimer's, slowing disease progression but not restoring cognition. Sue Bell's case exemplifies the drug's effectiveness variance and high cost ($25,000+/year), posing challenges for widespread accessibility and long-term efficacy.

Showing 1 to 4 of 4 results